Patents Represented by Attorney Michael J. Sayles

Find this attorney in the Justia Lawyer Directory

  • 5-substituted ornithine derivatives
    Patent number: 4902719
    Abstract: This invention relates to ornithine derivatives substituted at the 5 position with an R group which can be a --CH.sub.2 F, --CHF.sub.2, --CHClF, --C.tbd.CH, --CH.dbd.CH.sub.2, or --CH.dbd.C.dbd.CH.sub.2 group and the pharmaceutically acceptable acid addition salts thereof which are specific inhibitors of OAT and can be used in the treatment of conditional deficiencies of ornithine.
    Type: Grant
    Filed: February 1, 1989
    Date of Patent: February 20, 1990
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Fritz E. Gerhart, Nikolaus J. Seiler
  • Reducing reperfusion injury with 1,3-dihydro-4-methyl-5-(4-methylthio)benzoyl)-2H-imidazol-2-thione
    Patent number: 4868197
    Abstract: A sulfur analog of enoximone, 1,3-dihydro-4-methyl-5-[4-(methylthio)benzoyl]-2H-imidazol-2-thione, is reported to reduce reperfusion injury, the injry which occurs when molecular oxygen is reintroduced into an ischemic tissue. The compound could be used to prevent much of the damage which occurs to the heart of a heart attack victim.
    Type: Grant
    Filed: March 21, 1988
    Date of Patent: September 19, 1989
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Richard A. Schnettler, Richard C. Dage, J. Martin Grisar, Frank P. Palopoli
  • Enhancement of prazosin
    Patent number: 4868182
    Abstract: This invention relates to the synergistic enhancement of certain antihypertensives by the conjunctive use of certain cardiotonic agents. More specifically, this invention relates to the enhancement of the blood pressure lowering effect achieved with alpha.sub.1 -adrenoceptor antagonists by the conjunctive administration of cardiotonic agents possessing the ability to specifically inhibit cyclic AMP-phosphodiesterase.
    Type: Grant
    Filed: February 3, 1988
    Date of Patent: September 19, 1989
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventor: Richard C. Dage
  • Cardiotonic alkanoyl and aroyl oxazolones
    Patent number: 4866182
    Abstract: Alkanoyl or aroyl oxazolones enhance myocardial contractile force and are useful as cardiotonics in the treatment of heart failure.
    Type: Grant
    Filed: February 18, 1988
    Date of Patent: September 12, 1989
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Richard A. Schnettler, Winton D. Jones, Richard C. Dage
  • Certain 3-carboxylate or 3-carbamyl-5-acyl-2-(1H)-pyridinones having cardiotonic properties
    Patent number: 4853395
    Abstract: Novel 5-acyl-2-(1H)pyridinones and their use as cardiotonic agents. Typical of the compounds is 5-acetyl-1,2-dihydro-6-methyl-2-oxo-3-pyridinecarbonitrile which is prepared by condensing anionic cyano acetamide with 3-[(dimethylamino)methylenyl]-2,4-pentanedione in an inert organic solvent.
    Type: Grant
    Filed: November 17, 1987
    Date of Patent: August 1, 1989
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Winton D. Jones, Richard A. Schnettler, Richard C. Dage
  • Novel alkoxyimino ether derivatives of 5-acyl-2(1H)-pyridinones
    Patent number: 4849522
    Abstract: This invention relates to alkoxyimino ether derivatives of 5-acyl-2(1H)-pyridinones and to their use as cardiotonic agents useful in treating cardiac failure, and to the process useful in the preparation thereof.
    Type: Grant
    Filed: March 10, 1988
    Date of Patent: July 18, 1989
    Assignee: Merrell Dow Pharmaceuticals
    Inventors: Winton D. Jones, Richard C. Dage, Richard A. Schnettler